KJIM :: Korean Journal of Internal Medicine

Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry

Therapeutic Advances in Musculoskeletal Disease.2024;[Epub] CrossRef

Potential Rheumatoid Arthritis-Associated Interstitial Lung Disease Treatment and Computational Approach for Future Drug Development

Eunji Jeong, Hyunseok Hong, Yeon-Ah Lee, Kyoung-Soo Kim

International Journal of Molecular Sciences.2024; 25(5): 2682. CrossRef

Efficacy and Safety of Conventional Synthetic, Biologic and Targeted Synthetic DMARDs in RA-ILD: A Narrative Review

Indian Journal of Rheumatology.2023; 18(4): 303. CrossRef

Retention Rate and Safety of Biologic and Targeted Synthetic DMARDs in Patients with RA-Associated Interstitial Lung Disease: A KOBIO Registry Study

Sun-Kyung Lee, Kichul Shin, Ju-Yang Jung, Chang-Hee Suh, Ji-Won Kim, Hyoun-Ah Kim

Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Haoming Yuan, Shaoxin Cui, Lin Yang, Jiehan Cui, Xiaoping Wang, Meng Ding, Lu Jin, Yanru Wang, Fei Chang, Hongtao Jin, Jun Ma, Min Shi, Aijing Liu

Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento

Javier Narváez, Petra Díaz del Campo Fontecha, Noé Brito García, Gema Bonilla, Myriam Aburto, Iván Castellví, Esteban Cano-Jiménez, Natalia Mena-Vázquez, M. Asunción Nieto, Ana María Ortiz, Claudia Valenzuela, Miguel Ángel Abad Hernández, Isabel Castrejón

SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment

Reumatología Clínica (English Edition).2022; 18(9): 501. CrossRef

Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology

Rheumatology Science and Practice.2022; 60(6): 517. CrossRef

Revisión sistemática sobre el impacto de los fármacos en la enfermedad pulmonar intersticial difusa asociada a Artritis Reumatoide

Carmen Carrasco Cubero, Eugenio Chamizo Carmona, Paloma Vela Casasempere

Diagnosis and management of connective tissue disease‐associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand*

Adelle S. Jee, Robert Sheehy, Peter Hopkins, Tamera J. Corte, Christopher Grainge, Lauren K. Troy, Karen Symons, Lissa M. Spencer, Paul N. Reynolds, Sally Chapman, Sally de Boer, Taryn Reddy, Anne E. Holland, Daniel C. Chambers, Ian N. Glaspole, Helen E.

Systematic review of the impact of drugs on diffuse interstitial lung disease associated with rheumatoid arthritis

Carmen Carrasco Cubero, Eugenio Chamizo Carmona, Paloma Vela Casasempere

Reumatología Clínica (English Edition).2021; 17(9): 504. CrossRef

Mini Review: Pulmonary Toxicity Secondary to Immunosuppressive Agents in the Treatment of Rheumatoid Arthritis.

SunKrist Journal of Orthopedics and Musculoskeletal Disorders.2021; : 1. CrossRef

Mortality in Korean Patients With Rheumatoid Arthritis

Journal of Rheumatic Diseases.2021; 28(3): 113. CrossRef

The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application

Yukai Wang, Shaoqi Chen, Shaoyu Zheng, Jianqun Lin, Shijian Hu, Jinghua Zhuang, Qisheng Lin, Xuezhen Xie, Kedi Zheng, Weijin Zhang, Guangzhou Du, Guohong Zhang, Anna-Maria Hoffmann-Vold, Marco Matucci-Cerinic, Daniel E. Furst

Factors associated with mortality in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis

Meihua Qiu, Jing Jiang, Xueyuan Nian, Yutie Wang, Pengfei Yu, Jie Song, Shenchun Zou

Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows

Giulia Cassone, Andreina Manfredi, Caterina Vacchi, Fabrizio Luppi, Francesca Coppi, Carlo Salvarani, Marco Sebastiani

Journal of Clinical Medicine.2020; 9(4): 1082. CrossRef

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Christopher R Holroyd, Rakhi Seth, Marwan Bukhari, Anshuman Malaviya, Claire Holmes, Elizabeth Curtis, Christopher Chan, Mohammed A Yusuf, Anna Litwic, Susan Smolen, Joanne Topliffe, Sarah Bennett, Jennifer Humphreys, Muriel Green, Jo Ledingham

Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD)

Reinterpreting Evidence of Rheumatoid Arthritis-Associated Interstitial Lung Disease to Understand Etiology

Emily K. Wu, Robert D. Ambrosini, R. Matthew Kottmann, Christopher T. Ritchlin, Edward M. Schwarz, Homaira Rahimi

Current Rheumatology Reviews.2019; 15(4): 277. CrossRef

Biologics-induced interstitial lung diseases in rheumatic patients: facts and controversies

Juan Chen, Shuhong Chi, Feng Li, Jiali Yang, William C. Cho, Xiaoming Liu

Expert Opinion on Biological Therapy.2017; 17(3): 265. CrossRef

Treatment of connective tissue disease-associated interstitial lung disease: the pulmonologist’s point of view

The Korean Journal of Internal Medicine.2017; 32(4): 600. CrossRef

Acute Respiratory Events in Connective Tissue Disorders

Spyros A. Papiris, Effrosyni D. Manali, Likurgos Kolilekas, Konstantinos Kagouridis, Maria Maniati, Gerasimos Filippatos, Demosthenes Bouros

Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis

Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine.2015; 9s1: CCRPM.S23288. CrossRef